Artikel
Safety first? Drug-related problems at admission to surgery: A retrospective study
Suche in Medline nach
Autoren
-
Stephanie Clemens
- Institute of Pharmacy, Pharmaceutical Biology and Clinical Pharmacy, Paracelsus Medical University, Salzburg, Austria
-
Clara Simon
- Institute of Pharmacy, Pharmaceutical Biology and Clinical Pharmacy, Paracelsus Medical University, Salzburg, Austria
-
Karin Kanduth
- Institute of Pharmacy, Pharmaceutical Biology and Clinical Pharmacy, Paracelsus Medical University, Salzburg, Austria
-
Olaf Rose
- Institute of Pharmacy, Pharmaceutical Biology and Clinical Pharmacy, Paracelsus Medical University, Salzburg, Austria
| Veröffentlicht: | 7. November 2023 |
|---|
Gliederung
Text
Background: Inappropriate preoperative management in medication may lead to unnecessary risks and complications. Research on medication management is scare for surgery. This study aimed to characterize emerging drug-related problems at admission in patients undergoing elective surgery.
Materials and methods: The study was designed as a retrospective, observational study at admission for nine different surgical sites at a university hospital. Included were all patients undergoing elective surgery in 2021 with ≥1 drug-related problems. The sample size was calculated considering 95% confidence interval and 5% precision. Prevalence and nature of drug-related problems during a medication review were classified according to the Pharmaceutical Network Europe classification of drug-related problems, V9.1 and the Hatoum scale of clinical significance. Drugs were grouped into the Anatomical-Therapeutic-Chemical classification system of the World Health Organization. The Charlson Comorbidity Index was applied to assess morbidity of participants. Analyses were conducted using descriptive statistics.
Results: The preliminary sample included >10,000 elective surgical patients. Participants’ most common morbidities were cancers (34%), diabetes mellitus with end organ damage (26%), and peripheral vascular diseases (19%). Around 2% of this sample showed drug-related problems. Major causes were drug-drug interactions and supra-therapeutic dosing. Most drug-related problems were rated as clinically significant. Cardiovascular drugs were the drug class of major concern. Half of the drug-related problems were caused by just a dozen of drugs. Simvastatin (interactions) and missing pantoprazole were typical examples.
Conclusion: The study showed that patients at surgery admissions totally differ from most medication review study cohorts. As drug-related problems are rare but meaningful, patient selection would contribute to an efficient process. At this stage of the hospital course, a medication review should mainly focus on medication safety aspects.
References
- 1.
- Griese-Mammen N, Hersberger KE, Messerli M, Leikola S, Horvat N, van Mil JWF, Kos M. PCNE definition of medication review: reaching agreement. Int J Clin Pharm. 2018 Oct;40(5):1199-208. DOI: 10.1007/s11096-018-0696-7
- 2.
- Howard RL, Avery AJ, Slavenburg S, Royal S, Pipe G, Lucassen P, Pirmohamed M. Which drugs cause preventable admissions to hospital? A systematic review. Br J Clin Pharmacol. 2007 Feb;63(2):136-47. DOI: 10.1111/j.1365-2125.2006.02698.x
- 3.
- Roughead EE, Gilbert AL, Primrose JG, Sansom LN. Drug-related hospital admissions: a review of Australian studies published 1988-1996. Med J Aust. 1998 Apr 20;168(8):405-8. DOI: 10.5694/j.1326-5377.1998.tb138996.x
- 4.
- Rose O, Jaehde U, Köberlein-Neu J. Discrepancies between home medication and patient documentation in primary care. Res Social Adm Pharm. 2018 Apr;14(4):340-6. DOI: 10.1016/j.sapharm.2017.04.003
- 5.
- Mekonnen AB, McLachlan AJ, Brien JA. Effectiveness of pharmacist-led medication reconciliation programmes on clinical outcomes at hospital transitions: a systematic review and meta-analysis. BMJ Open. 2016 Feb 23;6(2):e010003. DOI: 10.1136/bmjopen-2015-010003
- 6.
- Willeboordse F, Schellevis FG, Meulendijk MC, Hugtenburg JG, Elders PJM. Implementation fidelity of a clinical medication review intervention: process evaluation. Int J Clin Pharm. 2018 Jun;40(3):550-65. DOI: 10.1007/s11096-018-0615-y
- 7.
- Rose O, Mennemann H, John C, Lautenschläger M, Mertens-Keller D, Richling K, Waltering I, Hamacher S, Felsch M, Herich L, Czarnecki K, Schaffert C, Jaehde U, Köberlein-Neu J. Priority Setting and Influential Factors on Acceptance of Pharmaceutical Recommendations in Collaborative Medication Reviews in an Ambulatory Care Setting - Analysis of a Cluster Randomized Controlled Trial (WestGem-Study). PLoS One. 2016 Jun 2;11(6):e0156304. DOI: 10.1371/journal.pone.0156304
- 8.
- Buchegger S, Iglseder B, Alzner R, Kogler M, Rose O, Kutschar P, Krutter S, Dückelmann C, Flamm M, Pachmayr J. Patient perspectives on, and effects of, medication management in geriatric fallers (the EMMA study): protocol for a mixed-methods pre-post study. BMJ Open. 2023 Feb 22;13(2):e066666. DOI: 10.1136/bmjopen-2022-066666
- 9.
- Köberlein-Neu J, Mennemann H, Hamacher S, Waltering I, Jaehde U, Schaffert C, Rose O. Interprofessional Medication Management in Patients With Multiple Morbidities. Dtsch Arztebl Int. 2016 Nov 4;113(44):741-8. DOI: 10.3238/arztebl.2016.0741
- 10.
- Schindler E, Richling I, Rose O. Pharmaceutical Care Network Europe (PCNE) drug-related problem classification version 9.00: German translation and validation. Int J Clin Pharm. 2021 Jun;43(3):726-30. DOI: 10.1007/s11096-020-01150-w
- 11.
- Oki T, Ishii S, Furukawa K, Shono A, Akazawa M. Assessment of the potential impact of resolving drug-related problems by clinical pharmacists in Japan: a retrospective observational study. J Pharm Health Care Sci. 2021 Dec 6;7(1):47. DOI: 10.1186/s40780-021-00232-9
- 12.
- Rose O, Richling I, Voigt K, Gottschall M, Köberlein-Neu J. Patient selection and general practitioners' perception of collaboration in medication review. Res Social Adm Pharm. 2019 May;15(5):521-7. DOI: 10.1016/j.sapharm.2018.06.019
- 13.
- Rose O, Cheong VL, Dhaliwall S, Eislage K, Erzkamp S, Jorgenson D, Martínez F, Luetsch K. Standards in medication review: An international perspective. Can Pharm J (Ott). 2020 Jul 14;153(4):215-23. DOI: 10.1177/1715163520929665
